Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 53.52 Billion KRW | 18.44% |
| 2022 | 45.19 Billion KRW | 29.18% |
| 2021 | 34.98 Billion KRW | -9.97% |
| 2020 | 38.85 Billion KRW | -23.76% |
| 2019 | 50.96 Billion KRW | 12.29% |
| 2018 | 45.38 Billion KRW | -21.06% |
| 2017 | 57.49 Billion KRW | 182.22% |
| 2016 | 20.37 Billion KRW | -7.01% |
| 2015 | 21.9 Billion KRW | -47.03% |
| 2014 | 41.36 Billion KRW | 8.2% |
| 2013 | 38.22 Billion KRW | -16.18% |
| 2012 | 45.6 Billion KRW | -16.71% |
| 2011 | 54.75 Billion KRW | -20.49% |
| 2010 | 68.86 Billion KRW | -6.23% |
| 2009 | 73.44 Billion KRW | 10.7% |
| 2008 | 66.34 Billion KRW | 48.07% |
| 2007 | 44.8 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 42.61 Billion KRW | -1.61% |
| 2024 Q1 | 43.31 Billion KRW | -19.09% |
| 2023 Q3 | 43.63 Billion KRW | -12.61% |
| 2023 Q4 | 53.52 Billion KRW | 22.69% |
| 2023 FY | 53.52 Billion KRW | 18.44% |
| 2023 Q1 | 43.32 Billion KRW | -4.14% |
| 2023 Q2 | 49.92 Billion KRW | 15.24% |
| 2022 FY | 45.19 Billion KRW | 29.18% |
| 2022 Q2 | 32.77 Billion KRW | -7.18% |
| 2022 Q1 | 35.31 Billion KRW | 0.94% |
| 2022 Q4 | 45.19 Billion KRW | 39.87% |
| 2022 Q3 | 32.31 Billion KRW | -1.42% |
| 2021 Q2 | 41.28 Billion KRW | 2.83% |
| 2021 FY | 34.98 Billion KRW | -9.97% |
| 2021 Q1 | 40.14 Billion KRW | 3.31% |
| 2021 Q3 | 39.12 Billion KRW | -5.22% |
| 2021 Q4 | 34.98 Billion KRW | -10.58% |
| 2020 FY | 38.85 Billion KRW | -23.76% |
| 2020 Q4 | 38.85 Billion KRW | -0.83% |
| 2020 Q1 | 45.69 Billion KRW | -10.35% |
| 2020 Q3 | 39.18 Billion KRW | -3.9% |
| 2020 Q2 | 40.77 Billion KRW | -10.75% |
| 2019 Q4 | 50.96 Billion KRW | -5.4% |
| 2019 FY | 50.96 Billion KRW | 12.29% |
| 2019 Q1 | 43.45 Billion KRW | -4.26% |
| 2019 Q2 | 56.56 Billion KRW | 30.18% |
| 2019 Q3 | 53.87 Billion KRW | -4.75% |
| 2018 Q4 | 45.38 Billion KRW | -2.29% |
| 2018 Q1 | 51.69 Billion KRW | -10.09% |
| 2018 FY | 45.38 Billion KRW | -21.06% |
| 2018 Q2 | 47.3 Billion KRW | -8.49% |
| 2018 Q3 | 46.44 Billion KRW | -1.82% |
| 2017 Q2 | 19.53 Billion KRW | 0.76% |
| 2017 FY | 57.49 Billion KRW | 182.22% |
| 2017 Q4 | 57.49 Billion KRW | 149.17% |
| 2017 Q3 | 23.07 Billion KRW | 18.1% |
| 2017 Q1 | 19.39 Billion KRW | -4.82% |
| 2016 Q3 | 20.22 Billion KRW | -9.65% |
| 2016 FY | 20.37 Billion KRW | -7.01% |
| 2016 Q1 | 20.95 Billion KRW | -4.36% |
| 2016 Q2 | 22.38 Billion KRW | 6.85% |
| 2016 Q4 | 20.37 Billion KRW | 0.72% |
| 2015 Q1 | 38.65 Billion KRW | -6.55% |
| 2015 FY | 21.9 Billion KRW | -47.03% |
| 2015 Q4 | 21.9 Billion KRW | 8.97% |
| 2015 Q3 | 20.1 Billion KRW | -46.44% |
| 2015 Q2 | 37.53 Billion KRW | -2.89% |
| 2014 Q1 | 35.31 Billion KRW | -7.62% |
| 2014 FY | 41.36 Billion KRW | 8.2% |
| 2014 Q2 | 36.98 Billion KRW | 4.73% |
| 2014 Q4 | 41.36 Billion KRW | 11.24% |
| 2014 Q3 | 37.18 Billion KRW | 0.53% |
| 2013 Q4 | 38.22 Billion KRW | -0.99% |
| 2013 FY | 38.22 Billion KRW | -16.18% |
| 2013 Q1 | 43.76 Billion KRW | -4.03% |
| 2013 Q2 | 41.96 Billion KRW | -4.11% |
| 2013 Q3 | 38.6 Billion KRW | -8.0% |
| 2012 FY | 45.6 Billion KRW | -16.71% |
| 2012 Q4 | 45.6 Billion KRW | 0.0% |
| 2012 Q1 | 49.23 Billion KRW | 0.0% |
| 2011 FY | 54.75 Billion KRW | -20.49% |
| 2011 Q3 | 49.53 Billion KRW | -18.7% |
| 2011 Q1 | 69.31 Billion KRW | 0.65% |
| 2011 Q2 | 60.92 Billion KRW | -12.1% |
| 2010 Q3 | 75.92 Billion KRW | 1.23% |
| 2010 Q1 | 72.96 Billion KRW | -0.66% |
| 2010 Q2 | 75 Billion KRW | 2.79% |
| 2010 FY | 68.86 Billion KRW | -6.23% |
| 2010 Q4 | 68.86 Billion KRW | -9.29% |
| 2009 FY | 73.44 Billion KRW | 10.7% |
| 2009 Q4 | 73.44 Billion KRW | 1.45% |
| 2009 Q3 | 72.39 Billion KRW | 6.96% |
| 2009 Q2 | 67.68 Billion KRW | 2.69% |
| 2009 Q1 | 65.91 Billion KRW | -0.66% |
| 2008 Q2 | 46.29 Billion KRW | 3.76% |
| 2008 Q1 | 44.61 Billion KRW | -0.42% |
| 2008 Q3 | 45.54 Billion KRW | -1.63% |
| 2008 Q4 | 66.34 Billion KRW | 45.69% |
| 2008 FY | 66.34 Billion KRW | 48.07% |
| 2007 Q3 | 45.89 Billion KRW | 4.37% |
| 2007 Q1 | 38.84 Billion KRW | 0.0% |
| 2007 Q2 | 43.97 Billion KRW | 13.19% |
| 2007 FY | 44.8 Billion KRW | 0.0% |
| 2007 Q4 | 44.8 Billion KRW | -2.37% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 31.248% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 94.243% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 92.43% |
| HANDOK Inc. | 449.7 Billion KRW | 88.097% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 37.518% |
| Yuhan Corporation | 712.33 Billion KRW | 92.486% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 91.529% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -236.775% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 93.716% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 74.0% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | 28.791% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 63.782% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | 23.966% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 31.248% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -46.91% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 78.687% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 75.747% |
| JW Holdings Corporation | 827.51 Billion KRW | 93.531% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 87.751% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 90.878% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 85.899% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 32.5% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | 23.495% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 77.958% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 83.794% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 31.248% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 89.076% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 93.761% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 85.899% |
| Yuhan Corporation | 712.33 Billion KRW | 92.486% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 88.797% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 60.919% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 89.64% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 85.899% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 65.362% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 40.501% |
| CKD Bio Corp. | 170.76 Billion KRW | 68.653% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 78.038% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 66.047% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -24.43% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 32.5% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 91.537% |
| Boryung Corporation | 373.1 Billion KRW | 85.653% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 74.289% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 74.0% |
| JW Lifescience Corporation | 96.44 Billion KRW | 44.497% |